LivaNova PLC (NASDAQ:LIVN) Shares Bought by Atria Investments Inc

Atria Investments Inc grew its holdings in LivaNova PLC (NASDAQ:LIVN) by 6.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,653 shares of the company’s stock after acquiring an additional 331 shares during the quarter. Atria Investments Inc’s holdings in LivaNova were worth $297,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of LIVN. Emerald Advisers LLC increased its holdings in LivaNova by 2.1% in the 3rd quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock worth $36,542,000 after buying an additional 14,302 shares during the period. abrdn plc increased its stake in shares of LivaNova by 43.8% in the third quarter. abrdn plc now owns 232,025 shares of the company’s stock worth $12,191,000 after acquiring an additional 70,618 shares during the period. State of Alaska Department of Revenue raised its holdings in shares of LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock valued at $41,889,000 after purchasing an additional 25,277 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in LivaNova by 11.8% in the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 19,000 shares of the company’s stock valued at $998,000 after purchasing an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 0.7 %

Shares of NASDAQ LIVN opened at $51.32 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.79 billion, a PE ratio of 122.19 and a beta of 1.01. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The stock has a fifty day simple moving average of $52.13 and a 200-day simple moving average of $52.60.

Analysts Set New Price Targets

A number of research analysts have issued reports on LIVN shares. Robert W. Baird boosted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.